Expertise in
4
conditions

Dr. Kerem Ozer

Endocrinology
Office
110 Deer Ridge Dr, 
Round Rock, TX 
Accepting New Patients
Referral required
Before you request
Expertise in
4
conditions
Office
110 Deer Ridge Dr, 
Round Rock, TX 

Overview

Kerem Ozer is an Endocrinologist practicing medicine in Round Rock, Texas.

Dr. Ozer is highly rated in 4 conditions, according to our data. His clinical expertise encompasses Diabetic Ketoacidosis, Type 2 Diabetes (T2D), Type 1 Diabetes (T1D), and Juvenile Primary Osteoporosis.

He is actively involved in clinical research, co-authoring 13 peer reviewed articles and participating in 8 clinical trials. Dr. Ozer is currently accepting new patients.

Specialties

Endocrinology

Licenses

Internal Medicine in TX

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
FirstCare
  • HMO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO

Locations

Office
110 Deer Ridge Dr, Round Rock, TX 78681

Additional Areas of Focus

Dr. Ozer has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Hypoparathyroidism

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)
Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)
Enrollment Status: Completed
Publish Date: July 24, 2025
Intervention Type: Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
A Post- Approval Study to Evaluate the Long-term Safety and Effectiveness of the Eversense® Continuous Glucose Monitoring (CGM) System
A Post- Approval Study to Evaluate the Long-term Safety and Effectiveness of the Eversense® Continuous Glucose Monitoring (CGM) System
Enrollment Status: Completed
Publish Date: June 12, 2025
Intervention Type: Device
Study Phase: Not Applicable
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo After an Intensive Lifestyle Program in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double Blind, Placebo-Controlled Trial (SURMOUNT-3)
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo After an Intensive Lifestyle Program in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double Blind, Placebo-Controlled Trial (SURMOUNT-3)
Enrollment Status: Completed
Publish Date: May 16, 2024
Intervention Type: Other, Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
A Randomized, Phase 3, Open-label Trial Comparing the Effect of the Addition of Tirzepatide Once Weekly Versus Insulin Lispro (U100) Three Times Daily in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin (SURPASS-6)
A Randomized, Phase 3, Open-label Trial Comparing the Effect of the Addition of Tirzepatide Once Weekly Versus Insulin Lispro (U100) Three Times Daily in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin (SURPASS-6)
Enrollment Status: Completed
Publish Date: November 02, 2023
Intervention Type: Drug
Study Drugs: Tirzepatide, Insulin Lispro, Insulin Glargine
Study Phase: Phase 3
A Phase 2, Randomized, Parallel, Open-Label Comparator-Controlled Trial to Evaluate the Safety and Efficacy of LY3209590 in Study Participants With Type 1 Diabetes Mellitus Previously Treated With Multiple Daily Injection Therapy
A Phase 2, Randomized, Parallel, Open-Label Comparator-Controlled Trial to Evaluate the Safety and Efficacy of LY3209590 in Study Participants With Type 1 Diabetes Mellitus Previously Treated With Multiple Daily Injection Therapy
Enrollment Status: Completed
Publish Date: October 27, 2022
Intervention Type: Drug
Study Drugs: LY3209590, Insulin Degludec
Study Phase: Phase 2
Post Approval Study for Non-Adjunctive Use of Dexcom G5 and G6 CGM System for Diabetes Management
Post Approval Study for Non-Adjunctive Use of Dexcom G5 and G6 CGM System for Diabetes Management
Enrollment Status: Unknown
Publish Date: September 21, 2021
Intervention Type: Device
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog in Adults With Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog in Adults With Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion
Enrollment Status: Completed
Publish Date: January 22, 2021
Intervention Type: Drug
Study Phase: Phase 3
User Experience and Daily Use Patterns With the Integrated Insulin Management (IIM) System
User Experience and Daily Use Patterns With the Integrated Insulin Management (IIM) System
Enrollment Status: Completed
Publish Date: January 07, 2021
Intervention Type: Drug, Device
Study Phase: Not Applicable
View 7 Less Clinical Trials

13 Total Publications

Lower Risk of Cardiovascular Events in Patients With Clinical Atherosclerotic Cardiovascular Disease Who Initiated Semaglutide 2.4 mg in the Real-World: Results From the SCORE-Clinical ASCVD Study.
Lower Risk of Cardiovascular Events in Patients With Clinical Atherosclerotic Cardiovascular Disease Who Initiated Semaglutide 2.4 mg in the Real-World: Results From the SCORE-Clinical ASCVD Study.
Journal: Diabetes, obesity & metabolism
Published: December 19, 2025
Similar Doctors
Expertise in
69
conditions
Dr. Simona M. Scumpia
Endocrinology
Expertise in
69
conditions
Dr. Simona M. Scumpia
Endocrinology
Referral required
Before you request

Austin Thyroid And Endocrinology

2200 Park Bend Dr, Ste 300, 
Austin, TX 
 (6.0 miles away)
512-467-2727
Languages Spoken:
English, French, German, Romanian, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Simona Scumpia, MD, is board certified in Endocrinology and completed an internship as the University of Toronto. Her residency in internal medicine was at the University of Alberta in Edmonton, Canada. In addition, she fellowed in Endocrinology at the University of Pittsburgh. At the American College of Endocrinology, she was a fellow as well. After her fellowships, she was a professor of medicine at UTMB at Galveston as well as a director in the division of Endocrinology at CTMF. Dr. Scumpia is highly rated in 69 conditions, according to our data. Her clinical expertise encompasses Hypothyroidism, Obesity in Children, Vitamin D Deficiency, and Osteopenia. Dr. Scumpia is board certified in The American Board Of Internal Medicine - Endocrinology, Diabetes And Metabolism and The American Board Of Internal Medicine - Internal Medicine. Dr. Scumpia is currently accepting new patients.

Expertise in
16
conditions
Dr. Thomas C. Blevins
Endocrinology
Expertise in
16
conditions
Dr. Thomas C. Blevins
Endocrinology
Referral required
Before you request

Texas Diabetes And Endocrinology

6500 N Mopac Expy, Bldg 200, 
Austin, TX 
 (10.4 miles away)
512-458-8400
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Thomas Blevins is an Endocrinologist practicing medicine in Austin, Texas. Dr. Blevins is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Type 2 Diabetes (T2D), Type 1 Diabetes (T1D), Low Blood Sugar, and Thyroid Nodule. Dr. Blevins is board certified in The American Board Of Internal Medicine - Endocrinology, Diabetes And Metabolism and The American Board Of Internal Medicine - Internal Medicine. Dr. Blevins is currently accepting new patients.

Expertise in
19
conditions
Dr. Anupama T. Reddy
Endocrinology
Expertise in
19
conditions
Dr. Anupama T. Reddy
Endocrinology
Referral required
Before you request

Baylor Scott & White Clinic - Round Rock 425 University

425 University Blvd, 
Round Rock, TX 
 (5.2 miles away)
512-509-0200
Languages Spoken:
English, Hindi, Telugu
See accepted insurances
Accepting New Patients
Offers Telehealth

Anupama Reddy is an Endocrinologist practicing medicine in Round Rock, Texas. Dr. Reddy is highly rated in 19 conditions, according to our data. Her clinical expertise encompasses Diabetic Nephropathy, Diabetic Neuropathy, Hyperparathyroidism, and Obesity in Children. Dr. Reddy is board certified in Endocrinology Diabetes And Metabolism- American Osteopathic Board Of Internal Medicine. Dr. Reddy is currently accepting new patients.

Frequently Asked Questions about Dr. Kerem Ozer

How do I make an appointment with Dr. Kerem Ozer?

You can book an appointment with Dr. Kerem Ozer by calling their office at 512-715-3000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Kerem Ozer a top-rated expert for Diabetic Ketoacidosis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Kerem Ozer is classified as an Advanced expert for Diabetic Ketoacidosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Kerem Ozer specialize in?

While Dr. Kerem Ozer is a Endocrinology, they have specific expertise in Diabetic Ketoacidosis, Type 2 Diabetes (T2D), and Type 1 Diabetes (T1D). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Endocrinology.

Does Dr. Kerem Ozer participate in research or clinical trials?

Yes. Dr. Kerem Ozer has published 13 articles and abstracts on conditions like Diabetic Ketoacidosis. You can view a list of Dr. Kerem Ozer's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Kerem Ozer accept my insurance?

Dr. Kerem Ozer accepts most major insurance plans, including Blue Cross Blue Shield and FirstCare. We recommend calling the office directly at 512-715-3000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ozer's expertise for a condition
ConditionClose
      View All 32 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile